J 2024

Sentinel lymph node pathological ultrastaging: Final outcome of the Sentix prospective international study in patients with early-stage cervical cancer

KOCIAN, Roman; Christhardt KOHLER; Sylva BAJSOVA; Jiří JARKOVSKÝ; Ignacio ZAPARDIEL et al.

Základní údaje

Originální název

Sentinel lymph node pathological ultrastaging: Final outcome of the Sentix prospective international study in patients with early-stage cervical cancer

Autoři

KOCIAN, Roman; Christhardt KOHLER; Sylva BAJSOVA; Jiří JARKOVSKÝ ORCID; Ignacio ZAPARDIEL; Di Martino GIAMPAOLO; Luc VAN LONKHUIJZEN; Borek SEHNAL; Octavio Arencibia SANCHEZ; Blanca GIL-IBANEZ; Fabio MARTINELLI; Jiri PRESL; Luboš MINÁŘ; Radovan PILKA; Peter KASCAK; Pavel HAVELKA; Martin MICHAL; Toon VAN GORP; Kristyna NEMEJCOVA; Pavel DUNDR a David CIBULA

Vydání

Gynecologic oncology, SAN DIEGO, ACADEMIC PRESS INC ELSEVIER SCIENCE, 2024, 0090-8258

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30214 Obstetrics and gynaecology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 4.100

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/24:00136695

Organizační jednotka

Lékařská fakulta

EID Scopus

Klíčová slova anglicky

Cervical cancer; Sentinel lymph node; Biopsy; Ultrastaging

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 5. 8. 2024 13:19, Mgr. Tereza Miškechová

Anotace

V originále

Objective. To report the outcome of SLN staging in the SENTIX international prospective trial of SLN biopsy in patients with cervical cancer with an intensive ultrastaging protocol and central quality control and to evaluate how the intensity of pathological assessment correlates with metastatic detection rate in SLNs. Methods. Eligible were patients with stages T1a1/LVSI+ to T1b2 (<4 cm, <= 2 cm for fertility sparing), common tumor types, no suspicious lymph nodes on imaging, and bilateral SLN detection. SLNs were examined intraoperatively , processed by an intensive protocol for ultrastaging (paraffin blocks sectioned completely in 150- mu m intervals/levels). SLNs from each site were submitted for central quality control. Results. In the SENTIX SLN study, 647 out of 733 enrolled patients underwent SLN ultrastaging, identifying 12.5% (81/647) with node positive, N1 cases. Intraoperative detection revealed metastases in 56.8% (46/81) of these cases, categorized into macrometastases (83.7%), micrometastases (26.3%) , isolated tumor cells (9.1%). Ultrastaging identified additional metastatic involvement in 43.2% (35/81) of patients, with detailed sectioning revealing metastases (MAC/MIC) at first level in 20 cases (24.7%), at levels 2 -4 in 9 cases (11.1%), and at level >= 5 in 6 cases (7.4%). Conclusion. SLN ultrastaging detects additional 43% of N1 (MAC/MIC) in patients with negative LNs by imaging and intraoperative pathological assessment. The detection rate of positive SLN correlates with the intensity (number of levels) of ultrastaging. Examination of four levels from paraffin blocks, which detects >90% of patients with N1, is a reasonable compromise for an international standard for ultrastaging.